67085-13-6

Basic information

• Product Name: Butoconazole
• Synonyms: 1-(4-(4-Chlorophenyl)-2-(2,6-dichlorophenylthio)-N-butyl)-1H-imidazole;1H-Imidazole, 1-(4-(4-chlorophenyl)-2-((2,6-dichlorophenyl)thio)butyl)-, nitrate;67085-14-7 (Nitrate)
• CAS NO: 67085-13-6
• Molecular Formula: C19H17Cl3N2S
• Molecular Weight: 411.77568
• Mol File: 67085-13-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 566.9 °C at 760 mmHg
• Flash Point: 296.7 °C
• Appearance: /
• Density: 1.32 g/cm³
• Vapor Pressure: 2.76E-12mmHg at 25°C
• Refractive Index: 1.633
• CAS DataBase Reference: Butoconazole(CAS DataBase Reference)
• NIST Chemistry Reference: Butoconazole(67085-13-6)
• EPA Substance Registry System: Butoconazole(67085-13-6)

Safety Data

• Hazardous Substances Data: 67085-13-6(Hazardous Substances Data)

Usage

Description

Butoconazole is a broad-spectrum antifungal medication primarily used for the treatment of vaginal yeast infections. It functions by inhibiting fungal growth and disrupting their cell membranes, which ultimately leads to the death of the fungi. Butoconazole is available in the form of a topical cream and is generally well-tolerated with minimal side effects, making it a safe and effective treatment option.

Uses

Used in Pharmaceutical Industry:
Butoconazole is used as an antifungal agent for the treatment of vaginal yeast infections. It is applied topically to the affected area, targeting and eliminating the fungi responsible for the infection. The medication is effective due to its ability to inhibit fungal growth and disrupt their cell membranes, leading to their eventual death. This makes Butoconazole a valuable asset in the management and treatment of vaginal yeast infections.

InChI:InChI=1/C19H17Cl3N2S/c20-15-7-4-14(5-8-15)6-9-16(12-24-11-10-23-13-24)25-19-17(21)2-1-3-18(19)22/h1-5,7-8,10-11,13,16H,6,9,12H2

Upstream product

• 64872-76-0 butoconazole 
• 67085-11-4 1-[2-hydroxy-4-(4-chlorophenyl)-n-butyl]imidazole 
• 59363-13-2 1-chloro-4-(4-chlorophenyl)-2-butanol 
• 104-83-6 1-Chloro-4-(chloromethyl)benzene 
• 67085-12-5 1-[2-chloro-4-(4-chlorophenyl)-n-butyl]imidazole 
• 24966-39-0 2,6-dichlorothiophenol 
• 874-72-6 4-chlorobenzylmagnesium chloride 
• 151837-96-6 (2S)-1-(p-toluenesulphonyloxy)-4-(4-chlorophenyl)butan-2-ol 
• 151837-95-5 (2R)-1-(p-toluenesulphonyloxy)-4-(4-chlorophenyl)butan-2-ol 
• 151909-78-3 (2R)-1-<2-hydroxy-4-(4-chlorophenyl)butyl>-1H-imidazole 
• 151909-79-4 (2S)-1-<2-hydroxy-4-(4-chlorophenyl)butyl>-1H-imidazole 
• 151837-98-8 Methanesulfonic acid (S)-3-(4-chloro-phenyl)-1-imidazol-1-ylmethyl-propyl ester 
• 151837-97-7 Methanesulfonic acid (R)-3-(4-chloro-phenyl)-1-imidazol-1-ylmethyl-propyl ester 

Relevant articles and documents

Solid phase extraction procedure coupled with the chiral LC-ESI-MS/MS method for the enantioseparation and determination of butoconazole enantiomers in rat plasma and tissues: application to the enantioselective study on pharmacokinetics and tissue distribution

In the present study, a highly rapid, sensitive and enantioselective method was developed and fully validated for the separation and determination of butoconazole enantiomers in rat plasma and tissues by liquid chromatography-electrospray ionization coupled with tandem mass spectrometry (LC-ESI-MS/MS). The analytes and internal standard (tioconazole) were both extracted from plasma and tissue samples by the solid phase extraction (SPE) procedure with C18 cartridges. Satisfactory enantioseparation was achieved on a Chiralpak IC column by using acetonitrile/10 mM aqueous ammonium acetate (90?:?10, v/v) as a mobile phase. Butoconazole enantiomers and IS were detected in the multiple reaction monitoring (MRM) mode with a positive electrospray ionization source. A comprehensive validation of this method was conducted over the concentration range of 0.5-250 ng mL-1, and good linearity was obtained for each enantiomer with correlation coefficient (R2) greater than 0.991. The mean extraction recoveries were higher than 90.4%, and the relative error was well within the admissible range of -8.0 to 9.1% and the relative standard deviation was less than 11.5%. All the validation data demonstrated that the desirable specificity, carry-over, linearity, sensitivity, accuracy, precision, extraction recovery, matrix effect and stability were attained from the proposed approach. After validation, the established method was successfully applied to the study on stereoselective pharmacokinetics and tissue distribution in female Sprague-Dawley rats after transdermal administration of 10 mg kg-1 2% rac-butoconazole nitrate cream. It should be noted that this is the first report regarding the stereospecific study of butoconazole enantiomers in vivo. This journal is

Preparation method of butoconazole nitrate

The invention discloses a preparation method of butoconazole nitrate. The preparation method comprises the following steps: with 4-chlorobenzyl chloride as a starting raw material, synthesizing 1-chloro-4-(4-chlorophenyl)-2-butanol, then synthesizing 1-(4-(4-chlorophenyl)-2-hydroxy-butyl) imidazole, then synthesizing 1-(4-(4-chlorophenyl)-2-chloro-butyl) imidazole, adding the 1-(4-(4-chlorophenyl)-2-chloro-butyl) imidazole, 2, 6-dichlorobenzenethiol and potassium carbonate into acetone, heating for refluxing, adding water and ethyl acetate after the completion of a reaction, performing liquid separation, sequentially washing an ethyl acetate phase by using saturated potassium carbonate and saturated salt water, drying by using anhydrous magnesium sulfate, removing magnesium sulfate, dropwise adding nitric acid with the concentration of 65% in an ice bath until no precipitate is produced, filtering for collecting solid, and recrystallizing by using absolute ethanol to obtain white crystals, namely the butoconazole nitrate. By the preparation method of the butoconazole nitrate, the process is simple, the yield is high, the cost is low, and the purity of the obtained product is high.